Cargando…

Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Detalles Bibliográficos
Autores principales:	Baidoun, Firas, Merjaneh, Zahi, Abd-Elhay, Fatma Abd-Elshahed, Kamel, Mohamed Gomaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214216/ https://www.ncbi.nlm.nih.gov/pubmed/34147028 http://dx.doi.org/10.1016/j.tranon.2021.101156

Ejemplares similares

A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2021)

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins, Elizabeth R, et al.
Publicado: (2021)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Post-dengue acute disseminated encephalomyelitis: A case report and meta-analysis
por: Kamel, Mohamed Gomaa, et al.
Publicado: (2017)

A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia
por: Christodoulou, Ilias, et al.
Publicado: (2023)

P1170: CAR-T THERAPY IS EFFECTIVE AND SAFE IN TREATING RELAPSED/REFRACTORY LYMPHOMA WITH MALIGNANT SEROUS CAVITY EFFUSION
por: Huang, Lefu, et al.
Publicado: (2023)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Weapons & armor
Publicado: (1978)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
por: Forsberg, Matthew H, et al.
Publicado: (2018)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
por: Kenkel, Troy J., et al.
Publicado: (2023)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
por: Hucks, George, et al.
Publicado: (2019)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Negligible heat strain in armored vehicle officers wearing personal body armor
por: Stewart, Ian B, et al.
Publicado: (2011)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3fadsqpc4fmhes8f5tsdmrg9hr